Rybelsus Is Ozempic in a Pill — Is It Just as Good?

People can’t stop talking about semaglutide (Ozempic, Wegovy), the buzzy diabetes and weight loss drug. Ozempic and Wegovy are injectable medications: Users prick themselves with a preloaded syringe once per week. But while the popularity of Ozempic has led to shortages, there’s been much less hype for Rybelsus, an oral form of semaglutide — the exact same drug.
What Is Rybelsus?
Diabetes 101: What Is Ozempic?

Next up video playing in 10 seconds
Is Rybelsus as Effective as Ozempic?
Rybelsus appears to be just as potent as Ozempic, but there’s a catch: It is only available in smaller doses.
While these results suggest that Rybelsus and Ozempic could be similarly effective for people with type 2 diabetes, the two drugs are not equivalent, practically speaking, because Ozempic is available in more powerful dosages.
Higher Doses of Rybelsus Are on the Way
In the coming years, higher doses of Rybelsus may become available. In 2023, Novo Nordisk announced that it would seek FDA approval for larger doses of oral semaglutide for the treatment of type 2 diabetes.
The PIONEER PLUS trial, which tested two experimental larger doses of oral semaglutide in people with type 2 diabetes, demonstrated that at the highest dose of 50 mg, the drug’s glucose-lowering and weight loss results were at least as good as those found in Ozempic 2 mg. Study participants had an A1C reduction of 2 percentage points, and weight loss of about 20 pounds.
Is Rybelsus Approved for Weight Loss?
Oral semaglutide is not yet approved as a weight loss therapy.
In the recent OASIS 1 trial, however, researchers tested the effect of a 50 mg dose of oral semaglutide for people who were overweight or had obesity. After using the drug for over one year, study participants lost an average of 15.1 percent of their total body weight. That amount of weight loss was about equal to that achieved by people using the maximum dose of injectable semaglutide, suggesting that an oral semaglutide weight loss pill could be just as effective as the injectable.
Novo Nordisk has already applied for regulatory approval for a semaglutide weight loss pill in both the United States and Europe.
In the meantime, some doctors are prescribing Rybelsus off-label as a weight loss therapy for people without diabetes, especially those who cannot tolerate Wegovy or who are unable to use needles.
How to Take Rybelsus
If there’s another reason that Rybelsus hasn’t quite caught on, it’s that taking the drug is arguably something of a hassle.
According to the instructions on the FDA label, you need to take Rybelsus on an empty stomach, every morning, 30 minutes before eating, drinking, or using any other oral medications. You may have up to 4 ounces of plain water only during this time. If you have your breakfast too early, the pill will be less effective. But if you wait longer than 30 minutes to eat, the pill’s absorption may be enhanced (which could also lead to more significant side effects).
By contrast, Ozempic is a single weekly injection and can be taken at any time of day, with or without meals.
Rybelsus and Side Effects
A substantial minority of Ozempic users experience gastrointestinal side effects. For some, the nausea, vomiting, or diarrhea subsides as the body gets acclimated to the drug. But others don’t feel better and end up quitting the drug entirely.
Clinical trials suggest that Rybelsus has similar side effects. A roughly similar proportion of Rybelsus study participants reported experiencing the most common side effects, including nausea, abdominal pain, diarrhea, and vomiting.
Rybelsus’ FDA label also warns of some of the same rare, serious side effects as Ozempic, including pancreatitis (inflammation of the pancreas) and acute kidney injury (a sudden decrease in kidney function).
Compounded Oral Semaglutide
Some online compounding pharmacies are now advertising “oral semaglutide,” but some of these products are not, in fact, equivalent to Rybelsus. These semaglutide pills are taken sublingually (dissolved under the tongue) rather than swallowed, and therefore have an entirely different mechanism for absorption.
Buyers should be wary of such products, as there has never been any published study of sublingual semaglutide, and the safety and efficacy of such substances may be questionable.
The Takeaway
- Rybelsus, an oral form of semaglutide, appears to be just as effective as Ozempic and Wegovy for diabetes management and weight loss, but it is only available in less powerful doses.
- In the coming years, larger doses for the treatment of both diabetes and obesity may become available.
- Rybelsus remains an effective therapy for type 2 diabetes, and may be especially useful for people with needle phobia or those who cannot take Ozempic for any other reason.
Resources We Trust
- Mayo Clinic: What Happens if You Take Too Much Semaglutide?
- DiaTribe: Rybelsus Now First-Line Therapy for Type 2 Diabetes
- Cleveland Clinic: Oral Diabetes Medications
- Harvard Health: Two Tricks to Make It Easier to Swallow Pills
- Scientific American: You Quit Ozempic or Wegovy. What Happens Next?
- Rybelsus — Highlights of Prescribing Information. U.S. Food and Drug Administration. April 2021.
- Kim JC, Park EJ, Na DH. Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals. Pharmaceuticals. December 19, 2022.
- Rodbard HW, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. October 7, 2019.
- Klobucar S, Belancic A, Bukša I, et al. Effectiveness of Oral versus Injectable Semaglutide in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia. Diabetology. February 2, 2024.
- Frías JP, et al. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg Versus 1.0 mg in Patients With Type 2 Diabetes (SUSTAIN FORTE): A Double-Blind, Randomised, Phase 3B Trial. The Lancet Diabetes & Endocrinology. September 2021.

Sean Hashmi, MD
Medical Reviewer
Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California. As the regional director for clinical nutrition and weight management at a prominent healthcare organization in Southern California, Dr. Hashmi oversees the development and implementation of cutting-edge nutritional programs and weight management strategies. With his innovative approach and unwavering commitment to providing evidence-based solutions, he is a highly sought-after speaker and a leader in his field.
Hashmi founded the nonprofit organization SelfPrinciple.org to provide accessible and accurate health, nutrition, and wellness information to the public. Through this platform, he shares the latest research findings, empowering individuals to make informed decisions about their well-being. Self Principle also supports children's education by providing scholarships, books, and supplies, so that students have the resources necessary to succeed academically and build a brighter future.

Ross Wollen
Author
Ross Wollen joined Everyday Health in 2021 and now works as a senior editor, often focusing on diabetes, obesity, heart health, and metabolic health. He previously spent over a decade as a chef and craft butcher in the San Francisco Bay Area. After he was diagnosed with type 1 diabetes at age 36, he quickly became an active member of the online diabetes community, eventually becoming the lead writer and editor of two diabetes websites, A Sweet Life and Diabetes Daily. Wollen now lives with his wife and children in Maine's Midcoast region.